While PARP1 inhibitors such as Veliparib and Olaparib—widely used in cancer therapy—have shown promise in rescuing TDP-43-induced cell death in ALS models, their broad inhibition of PARP1 raises concerns due to the enzyme’s essential roles in DNA repair and transcriptional regulation [149,150]. The gene discussed is PARP1; the disease is cancer.